Lilly to seek FDA approval for potential Alzheimer's drug

Thursday, June 24, 2021 | Tom Murphy, AP Health Writer


FILE- In this April 26, 2017, file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Shares of Eli Lilly and Co. jumped early Thursday, June 24, 2021, after the drugmaker said it will seek approval for its potential Alzheimer’s treatment later this year. (AP Photo/Darron Cummings, File)

INDIANAPOLIS (AP) — Eli Lilly is nearly ready to take another shot at getting approval for a possible Alzheimer’s drug.

The drugmaker said Thursday that it plans to submit its potential treatment donanemab to the Food and Drug Administration later this year.

The announcement comes a few weeks after the FDA approved a treatment from rival Biogen, despite warnings from the agency’s independent advisers that it hasn’t been shown to help slow the brain-destroying disease.

The agency approved Biogen’s Aduhelm based on study results showing it seemed “reasonably likely” to benefit Alzheimer’s patients. It’s the first new Alzheimer’s drug in nearly 20 years and the only therapy that U.S. regulators have said can likely alter the course of the disease, rather than temporarily ease symptoms like thinking problems, memory lapses and anxiety.

Both Aduhelm and Lilly’s potential treatment, donanemab, help clear a protein called beta-amyloid from the brain.

Lilly said Thursday that it will seek approval for donanemab based on results from a mid-stage clinical study of the drug involving 272 patients with an early form of the disease. Researchers said donanemab showed signs of slowing a decline in cognition and daily function for patients who took it compared to those who took a placebo or fake drug.

The FDA gave donanemab a “breakthrough therapy” designation, which is intended to speed the development and review of drugs that show signs of being an improvement over established treatments.

Lilly may be able to file its application for approval in the next two or three months since the drugmaker appears to have all the data it needs, said Dr. Vamil Divan, an analyst who covers the company for Mizhuho Securities USA.

The Indianapolis company also will examine the drug in a larger, late-stage study. A spokeswoman said Lilly plans to complete enrollment in that study by the end of the year, and an 18-month treatment period will follow.

Biogen said Wednesday that another experimental Alzheimer’s treatment it developed with Japan’s Eisai Co. also received a breakthrough therapy designation from the FDA. Researchers are examining that drug, lecanemab, in a late-stage study.

The companies gave no time frame for when they might seek regulatory approval.

Some 6 million people in the U.S. and many more worldwide have Alzheimer’s disease, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks.

Lilly and several other drugmakers have previously failed in attempts to find a treatment that slows the progression of the mind-robbing disease.

More than four years ago, Lilly said another potential drug it developed called solanezumab did not work better than a placebo in a study of over 2,100 people.

That drug also aimed to clear potentially harmful protein from the brain.

Eli Lilly and Co. shares jumped $15.87, or 7.3%, to close Thursday at $232.97, while the Standard & Poor’s 500 index climbed less than 1%.

Shares of Biogen fell 6.1%, or $22.74, to end the day at $349.16.

___

Follow Tom Murphy on Twitter: @thpmurphy

Should you invest $1,000 in Eli Lilly and right now?

Before you consider Eli Lilly and, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and wasn't on the list.

While Eli Lilly and currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Eli Lilly and (LLY)2.7$246.60+1.3%1.38%36.86Buy$231.29
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.